Using Bacteriophages to Reverse Antibiotic Resistance of Pathogens

Summary of the technology

We have demonstrated a proof of principle for sensitization of a laboratory strain of E. coli to streptomycin and to nalidixic acid using a lambda phage as a gene delivery vehicle. The phage infects E. coli and transfers genes conferring dominant sensitivity to antibiotics (rpsL and gyrA). The infected bacteria are favored in the environmental settings due to the presence of a resistance gene to a disinfectant agent, tellurite, in the phage genome (1).
Short term commercialization plans (2-3 years):
• Show that the lambda phage is effectively lysogenizing bacteria on environmental surfaces, not only in solutions or petri dishes.
• Adapt the lambda phage to an E. coli pathogenic host by repeated selection cycles.
• Alternatively, transfer the sensitization cassette to another phage.
• Test the efficiency of the delivery vehicle to enrich the drug-sensitive pathogen population in mice cages, which will be sprayed with pathogens, phages and tellurite to simulate hospital settings.
• Test whether mice in treated cages vs. mice in untreated cages can be cured using antibiotics to which the pathogens are resistant.
• Test efficiency of use in hospital settings (Dr. Daniel T. Laish, Director of ICU in a Florida-based hospital offered to carry out the research in their facilities).
• Obtain an FDA license.
Long term goals (3-6 years):
• Obtain temperate phage specific for different pathogens (MRSA, VRE, etc.) from different collections, or isolate new temperate phages.
• Genetically engineer to harbor the cassette encoding rpsL, gyrA (conferring dominant sensitivity), and tellurite-resistance (for selection).
• Test the efficiency of the delivery vehicle to enrich the drug-sensitive pathogen population in mice cages, which will be sprayed with pathogens, phages and tellurite to simulate hospital settings.
• Test whether mice in treated cages vs. mice in untreated cages can be cured using antibiotics to which the pathogens are resistant.
• Obtain an FDA license.

Project ID : 2-2012-282

Details of the Technology Offer

Technology
A Novel complex of engineered phages that deliver uniquely programmed CRISPR-Cas constructs into bacteria to reverse their antibiotic resistance.

The Need & Solution
The increasing threat of pathogen resistance to antibiotics requires the development of novel antimicrobial strategies. Bacterial pathogens evolve to overcome the therapeutic effect of antibiotics simply because antibiotics kill bacteria that are not resistant to them. This selective pressure that kills sensitive bacteria but not antibiotic-resistant bacteria is applied in each use of antibiotics. Currently, there is no approach that exerts selection pressure, which counteracts the selective pressure formed by antibiotics, i.e., a selection pressure that favorably changes the ratio of antibiotic-sensitive pathogens over antibiotic-resistant pathogens. Applying such a selection pressure will actively increase ratio of antibiotic-sensitive bacteria, and treat the core problem of antibiotic-resistance formation rather than its symptoms. Here we propose a genetic strategy that aims to sensitize bacteria to antibiotics and selectively kill antibiotic-resistant bacteria. We will use temperate phages to deliver a functional CRISPR-Cas system into the genome of antibiotic-resistant bacteria. The delivered CRISPR-Cas system will be programmed to destroy both antibiotic resistance-conferring plasmids and genetically modified lytic phages. This linkage between antibiotic-sensitization and protection from lytic phages is a key feature of the strategy. It allows programming of lytic phages to kill only antibiotic-resistant bacteria while protecting antibiotic-sensitized bacteria.

Potential Applications
This proposed technology has several potential human clinical applications, for addressing antibiotic resistance in human bacterial pathogens, by applying a constant selective pressure that will force bacteria to select for maintaining antibiotic sensitivity genetic properties. The first product developed from this technology is a “superphage spray product” aimed as a biological disinfectant for significantly lowering the percentage of antibiotic-resistant bacteria in hospital settings, in particular on hands of medical personnel.

Stage of Development: POC in non-pathogenic bacteria

Patents: One US granted patent (number 8,865,158) and one pending patent application

Supporting Publications
Yosef, I., Manor, M., Kiro, R., and Qimron, U. (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proceedings of the National Academy of Sciences USA, in press, 2015.
Edgar, R., Friedman, N., Molshanski-Mor, S. and Qimron, U. (2011) Reversing Bacterial Resistance to Antibiotics by Phage-Mediated Delivery of Dominant Sensitive Genes. Appl Environ Microbiol.
Jermy, A. (2012) Antimicrobials: Reversing resistance with phage. Nat Rev Microbiol, 10, 83.
Lukits A (2012) A New Weapon in the Fight Against Superbugs. The Wall Street Journal 17/1/2012.

Click here to read Haaretz story from 13/11/2013 - English version

Click here to read Haaretz story from 12/11/2013 - Hebrew version


Project manager

Adi Elkeles
BD Manager

Project researchers

Ehud Qimron
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Clinical Microbiology and Immunology

Rotem Edgar
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Clinical Microbiology and Immunology

Related Keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Life Sciences and Biotechnology
  • Life Sciences and Biotechnology
  • RNA / DNA therapy
  • Life Sciences and Biotechnology
  • Natural Compounds

About RAMOT at Tel Aviv University Ltd.

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.

RAMOT at Tel Aviv University Ltd.

Never miss an update from RAMOT at Tel Aviv University Ltd.

Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide

RAMOT at Tel Aviv University Ltd.

Send a request for information
to RAMOT at Tel Aviv University Ltd.

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support